0

The full content of Annals is available to subscribers

Subscribe/Learn More  >
Case Reports |

Cholera in a Vaccinated American: Immunological Response to Vaccination and Disease

E. ABRUTYN, M.D.; E. GANGAROSA, M.D.; J. FORREST, M.D.; and W. H. MOSLEY, M.D.
[+] Article and Author Information

Supported in part by Research Agreement 196802 between the National Institutes of Health, Bethesda, Md., and the Pakistan-SEATO Cholera Research Laboratory, Dacca, East Pakistan.

The Pakistan-SEATO Cholera Research Laboratory is a part of the SEATO Cholera Research Program and is supported by the U.S. Agency for International Development, Department of State, Washington, D.C.; the National Institutes of Health, Education, and Welfare, Washington, D.C.; and by the governments of Pakistan, United Kingdom, and other SEATO nations. The NIH Cholera Advisory Committee coordinates the research program.

▸Requests for reprints should be addressed to Elias Abrutyn, M.D., Center for Disease Control, Field Services Branch, Atlanta, Ga. 33033


Ann Intern Med. 1971;74(2):228-231. doi:10.7326/0003-4819-74-2-228
Text Size: A A A

A case of clinical cholera in an American physician and his serologic response to cholera vaccine and the illness are described. In July 1968 he participated in a study evaluating monovalent Inaba vaccine. Initially his vibriocidal antibody titers were lower than the geometric mean titers of the other nine study participants, but at 6 months his titer was comparable with titers of other Americans at 6 months after immunization. In December 1968 he traveled to East Pakistan from Atlanta, Georgia, and in January he had clinical cholera. Although the reciprocal vibriocidal antibody titer in the acute and convalescent serum specimens was unchanged (320), the reciprocal toxin neutralizing antibody titer rose from less than 1 on the day the illness began to 8 on the ninth day and 13 on the fifteenth day after onset. Whereas IgM vibriocidal antibody was detectable in sera collected before and after the illness, IgG vibriocidal antibody was detectable only in serum collected 15 days after onset. This case emphasizes that healthy persons inoculated with vaccine of proved efficacy can still develop clinical cholera when exposed to it.

Topics

cholera ; vaccination

Figures

Tables

References

Letters

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Comments

Submit a Comment
Submit a Comment

Summary for Patients

Clinical Slide Sets

Terms of Use

The In the Clinic® slide sets are owned and copyrighted by the American College of Physicians (ACP). All text, graphics, trademarks, and other intellectual property incorporated into the slide sets remain the sole and exclusive property of the ACP. The slide sets may be used only by the person who downloads or purchases them and only for the purpose of presenting them during not-for-profit educational activities. Users may incorporate the entire slide set or selected individual slides into their own teaching presentations but may not alter the content of the slides in any way or remove the ACP copyright notice. Users may make print copies for use as hand-outs for the audience the user is personally addressing but may not otherwise reproduce or distribute the slides by any means or media, including but not limited to sending them as e-mail attachments, posting them on Internet or Intranet sites, publishing them in meeting proceedings, or making them available for sale or distribution in any unauthorized form, without the express written permission of the ACP. Unauthorized use of the In the Clinic slide sets will constitute copyright infringement.

Toolkit

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Advertisement
Related Articles
Journal Club
Related Point of Care
Topic Collections
PubMed Articles
A brief history of vaccines & vaccination in India. Indian J Med Res 2014;139(4):491-511.

Buy Now

to gain full access to the content and tools.

Want to Subscribe?

Learn more about subscription options

Forgot your password?
Enter your username and email address. We'll send you a reminder to the email address on record.
(Required)
(Required)